Bernstein analyst Courtney Breen initiated coverage of Pfizer with a Market Perform rating and $32 price target The firm initiated coverage on U.S. biopharma and is optimistic on the outlook for the industry. However, in-line sector stock performance versus the S&P 500 Index and historically average valuations combined with increasing industry pressures suggest that investment outcomes will be more tied to specific company opportunities, the analyst tells investors in a research note. Bernstein says the market “clearly rewards future revenue growth – as a marker of portfolio reinvention.” It believes commercial realization will be increasingly constrained by concentration of competition and growing regulatory pressures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer palbociclib potentially effective for certain types of appendix cancer
- Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted
- ViiV Healthcare shares presentation on data for Apretude for HIV PrEP
- Guggenheim’s work with two former Pfizer executives strains relations, FT says
- GSK sues Moderna for U.S. patent infringement over COVID vaccines, Reuters says